(Q58614826)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

editorial

0 references

title

K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Josep Tabernero Caturla

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Francisco Javier Ramos

series ordinal

1

0 references

publication date

1 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

published in

Biomarkers in Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

97-99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

Network analysis of oncogenic Ras activation in cancer

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.97

RAS oncogenes: the first 30 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.97

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.97

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.97

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.97

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.97

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.97

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.97

21 January 2018

Identifiers

DOI

10.2217/17520363.2.2.97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477429%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference